Distribution of human papillomavirus types in cervical cancers in Hong Kong: Current situation and changes over the last decades

International Journal of Cancer

Volumn 125, Issue 7, 2009, Pages 1671-1677

  Chan, Paul K S ^a   Ho, Wendy C S ^a   Yu, Mei Ng ^b   Pong, Wai Mei ^c   Chan, Alexander C L ^c   Chan, Amanda K C ^c   Cheung, Tak Hong ^a   Wong, Martin C S ^b   To, Ka Fai ^a,b   Ng, Ho Keung ^b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

^c QUEEN ELIZABETH HOSPITAL   (Hong Kong)

Author keywords

Cervical cancer; Chinese; Hong Kong; Human papillomavirus; Type distribution; Type replacement

Indexed keywords

VIRUS DNA; WART VIRUS VACCINE;

ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ARTICLE; CANCER PREVENTION; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; FEMALE; FROZEN SECTION; HISTOPATHOLOGY; HONG KONG; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN TISSUE; MAJOR CLINICAL STUDY; MIXED INFECTION; NONHUMAN; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; VIRUS TYPING; WART VIRUS;

ADENOCARCINOMA; ADULT; AGED; ALPHAPAPILLOMAVIRUS; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, SQUAMOUS CELL; CHI-SQUARE DISTRIBUTION; FEMALE; HONG KONG; HUMANS; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PRECANCEROUS CONDITIONS; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

EID: 68549092528     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24495     Document Type: Article

References (37)

1. zur Hausen H. Papillomavirus and cancer: from basic studies to clinical application. Nat Rev Cancer 2002;2:342-50.
2. Muñoz N. Human papillomavirus and cancer: the epidemiological evidence. J Clin Virol 2000;19:1-5.
3. Franco EL, Rohan TE, Villa LL. Epidemiologic evidence and human papillomavirus infection as a necessary cause of cervical cancer. J Natl Cancer Inst 1999;91:506-11.
4. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19.
5. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27.
6. International Agency for Research on Cancer (IARC) working group. Human papillomaviruses. In: IARC. IARC monographs on the evaluation of carcinogenic risks to humans, vol. 90. Lyon: IARC Press, 2007.1-670.
7. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, Ghissassi FE. WHO International Agency for Research on Cancer. Carcinogenicity of human papillomaviruses. Lancet Oncol 2005;6:204.
8. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007;370:890-907.
9. Chan PK. Epidemiology of human papillomavirus in Asia: do HPV-52 and HPV-58 play a special role? Papillomavirus Rep 2005;16:265-71.
10. Clifford GM, Smith JS, Plummer M, Muñoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003;88:63-73.
11. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta analysis update. Int J Cancer 2007;121:621-32.
12. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G, HPV Vaccine Study group. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006;367:1247-55.
13. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter DL, Kitchener HC, Castellsague X, de Carvalho NS, Skinner SR, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007;369:2161-70.
14. Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-27.
15. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, Taddeo FJ, Railkar R, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928-43.
16. Arbyn M, Dillner J. Review of current knowledge on HPV vaccination: an appendix to the European guidelines for quality assurance in cervical cancer screening. J Clin Virol 2007;38:189-97.
17. Majewski S. Quadrivalent HPV6/11/16/18 vaccine (Gardasil): cross-protection against CIN and AIS caused by 10 oncogenic HPV types other than 16/18. EUROGIN 2008, Nice. Abstract No. TC 2-6.
18. Schiller JT, Castellsague X, Villa LL, Hildesheim A. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine 2008;26S:K53-K61.
19. Chan PK, Chan DP, To KF, Yu MY, Cheung JL, Cheng AF. Evaluation of extraction methods from paraffin wax embedded tissues for PCR amplification of human and viral DNA. J Clin Pathol 2001;54:401-3.
20. Muñoz N, Bosch FX, Castellsagué X, Díaz M, de Sanjose S, Hammouda D, Shah KV, Meijer CJ. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004;111:278-85.
21. Clifford GM, Gallus S, Herrero R, Muñoz N, Snijders PJ, Vaccarella S, Anh PT, Ferreccio C, Hieu NT, Matos E, Molano M, Rajkumar R, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the international agency for research on cancer HPV prevalence surveys: a pooled analysis. Lancet 2005;366:991-8.
22. Mendez F, Munoz N, Posso H, Molano M, Moreno V, van den Brule AJ, Ronderos M, Meijer C, Munoz A. Cervical coinfection with human papillomavirus (HPV) types and possible implications for the prevention of cervical cancer by HPV vaccines. J Infect Dis 2005;192:1158-65.
23. Trottier H, Mahmud S, Prado JC, Sobrinho JS, Costa MC, Rohan TE, Villa LL, Franco EL. Type-specific duration of human papillomavirus infection: implications for human papillomavirus screening and vaccination. J Infect Dis 2008;197:1436-47.
24. Bhatla N, Dar L, Rajkumar Patro A, Kumar P, Pati SK, Kriplani A, Gulati A, Broor S, Iyer VK, Mathur S, Shah KV, Gravitt PE. Human papillomavirus-type distribution in women with and without cervical neoplasia in north India. Int J Gynecol Pathol 2008;27:426-30.
25. Chan PK, Li WH, Chan MY, Ma WL, Cheung JL, Cheng AF. High prevalence of human papillomavirus type 58 in Chinese women with cervical cancer and precancerous lesions. J Med Virol 1999;59:232-8.
26. Chan PK, Cheung TH, Tam AO, Lo KW, Yim SF, Yu MM, To KF, Wong YF, Cheung JL, Chan DP, Hui M, Ip M. Biases in human papillomavirus genotype prevalence assessment associated with commonly used consensus primers. Int J Cancer 2006;118:243-5.
27. Huang LW, Hwang JL, Lin YH. Type-specific distribution of human papillomavirus in relation to grades of cervical neoplasia. Int J Clin Oncol 2006;92:143-4.
28. Wu EQ, Zhang GN, Yu XH, Ren Y, Fan Y, Wu YG, Kong W, Zha X. Evaluation of high-risk human papillomaviruses types distribution in cervical cancer in Sichuan province in China. BMC Cancer 2008;8:202.
29. Ding DC, Hsu HC, Huang RL, Lai HC, Lin CY, Yu MH, Chu TY. Type-specific distribution of HPV along the full spectrum of cervical carcinogenesis in Taiwan: an indication of viral oncogenic potential. Eur J Obstet Gynecol Reprod Biol 2008;140:245-51.
30. Prétet JL, Jacquard AC, Saunier M, Clavel C, Dachez R, Gondry J, Pradat P, Soubeyrand B, Leocmach Y, Mougin C, Riethmuller D, EDiTH study group. Human papillomavirus genotype distribution in low-grade squamous intraepithelial lesions in France and comparison with CIN2/3 and invasive cervical cancer: the EDiTH III study. Gynecol Oncol 2008;110:179-84.
31. Insinga RP, Liaw KL, Johnson LG, Madeleine MM. A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal and vulvar precancers and cancers in the United States. Cancer Epidemiol Biomarkers Prev 2008;17:1611-22.
32. Castellsagué X, Díaz M, de Sanjosé S, Muñoz N, Herrero R, Franceschi S, Peeling RW, Ashley R, Smith JS, Snijders PJ, Meijer CJ, Bosch FX, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 2006;5:303-15.
33. Chan PK, Lam CW, Cheung TH, Li WW, Lo KW, Chan MY, Cheung JL, Cheng AF. Association of human papillomavirus type 58 variant with the risk of cervical cancer. J Natl Cancer Inst 2002;94:1249-53.
34. Bao YP, Li N, Smith JS, Qiao YL. ACCPAB members. Human papillomavirus type distribution in women from Asia: a meta-analysis. Int J Gynecol Cancer 2008;18:71-9.
35. Liu SS, Tsang PC, Chan KY, Cheung AN, Chan KK, Leung RC, Ngan HY. Distribution of six oncogenic types of human papillomavirus and type 16 integration analysis in Chinese women with cervical precancerous lesions and carcinomas. Tumour Biol 2008;29:105-13.
36. Bertelsen BI, Kugarajh K, Skar R, Laerum OD. HPV subtypes in cervical cancer biopsies between 1930 and 2004: detection using general primer pair PCR and sequencing. Virchows Arch 2006;449:141-7.
37. Sigurdsson K, Taddeo FJ, Benediktsdottir KR, Olafsdottir K, Sigvaldason H, Oddsson K, Rafnar T. HPV genotypes in CIN 2-3 lesions and cervical cancer: a population-based study. Int J Cancer 2007;121:2682-7.